Psoriatic arthritis: pathogenesis and targeted therapies
AB Azuaga, J Ramírez, JD Cañete - International journal of molecular …, 2023 - mdpi.com
Psoriatic arthritis (PsA), a heterogeneous chronic inflammatory immune-mediated disease
characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis, and …
characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis, and …
Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies
NC Brembilla, WH Boehncke - Frontiers in Immunology, 2023 - frontiersin.org
Psoriasis is a common chronic inflammatory skin disease, associated with substantial
comorbidity. TH17 lymphocytes, differentiating under the influence of dendritic cell-derived …
comorbidity. TH17 lymphocytes, differentiating under the influence of dendritic cell-derived …
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double …
JF Merola, R Landewé, IB McInnes, PJ Mease… - The Lancet, 2023 - thelancet.com
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
IB McInnes, A Asahina, LC Coates, R Landewé… - The Lancet, 2023 - thelancet.com
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17A and IL-17F. We assessed the efficacy and safety of bimekizumab in patients with …
(IL)-17A and IL-17F. We assessed the efficacy and safety of bimekizumab in patients with …
Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
Background The causes for immune-mediated inflammatory diseases (IMIDs) are diverse
and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to …
and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to …
Signaling pathways and targeted therapies for psoriasis
J Guo, H Zhang, W Lin, L Lu, J Su… - Signal Transduction and …, 2023 - nature.com
Psoriasis is a common, chronic, and inflammatory skin disease with a high burden on
individuals, health systems, and society worldwide. With the immunological pathologies and …
individuals, health systems, and society worldwide. With the immunological pathologies and …
Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis
D McGonagle, P David, T Macleod… - Nature Reviews …, 2023 - nature.com
Since the original description of spondyloarthritis 50 years ago, results have demonstrated
similarities and differences between ankylosing spondylitis (AS) and axial psoriatic arthritis …
similarities and differences between ankylosing spondylitis (AS) and axial psoriatic arthritis …
Efficacy and safety of the TYK2/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial
P Mease, P Helliwell… - Arthritis & …, 2023 - Wiley Online Library
Objective Brepocitinib is a TYK2/JAK1 inhibitor in development for the treatment of several
immunologic diseases. The efficacy and safety of oral brepocitinib were assessed in …
immunologic diseases. The efficacy and safety of oral brepocitinib were assessed in …
Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II/III clinical studies in psoriasis and psoriatic arthritis
Introduction The benefit/risk profiles of biologics can be affected by comorbidities, certain
demographic characteristics, and concomitant medications; therefore, it is important to …
demographic characteristics, and concomitant medications; therefore, it is important to …
The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences
L Coates, L Gossec - Joint Bone Spine, 2023 - Elsevier
Management recommendations are helpful for clinicians and patients because they provide
guidelines for the use of medications [1]. In psoriatic arthritis (PsA), several recommendation …
guidelines for the use of medications [1]. In psoriatic arthritis (PsA), several recommendation …